Delcath Systems, Inc. (NASDAQ:DCTH) is considered one of the best medical device stocks to buy by analysts. H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on DCTH and raised the price target to $31 on August 6. The company’s HEPZATO product saw significant revenue growth in Q2, leading to the rating upgrade.

The growth was attributed to the solid adoption and performance of Delcath Systems, Inc.’s HEPZATO product. The company experienced a notable increase in sales, prompting the analyst to raise the price target. The activation of new treatment centers and expansion plans further supported revenue growth, indicating a strong market presence and potential for continued success.

Delcath Systems, Inc. (NASDAQ:DCTH) is a specialty pharmaceutical and medical devices company specializing in the treatment of primary and metastatic liver cancers. Their products include CHEMOSAT and HEPZATO. While DCTH shows promise as an investment, some believe AI stocks offer greater upside potential with lower risk.

For investors looking for hidden gems in the AI sector, the article suggests exploring other opportunities that may provide significant benefits. The article is originally published on Insider Monkey and offers insights into potential investment opportunities beyond Delcath Systems, Inc.

Read more at Yahoo Finance: H.C. Wainwright Remains Bullish on Delcath Systems (DCTH)